Find us on:

Research

Disease
Research Type
Reported as
Publication Type
Sort By
Total: 172
Enkephalin Therapy Improves Relapsing-Remitting Multiple Sclerosis
Research Type Human Reported as Case Report/Series/Restrospective Study Date January 28, 2020 Authors Chirag L. Patel, Ian S. Zagon, Gary A. Thomas and Patricia J. McLaughlin Institution Penn State University Disease MS (Multiple Sclerosis)
Multiple sclerosis (MS) is accompanied by decreases in serum endogenous enkephalin/endorphins and alterations in inflammatory cytokines. This retrospective analysis of serum levels was conducted in 53 patients with established relapsing-remitting MS treated with the disease-modifying therapies (DMT) glatiramer acetate, dimethyl fumarate or with the biotherapeutic low dose naltrexone (LDN) to elevate enkephalins, an off-label alternative. Opioid growth factor (OGF), an inhibitory endogenous opioi...
Improvement of Hailey-Hailey disease with low-dose naltrexone
Research Type Human Date January 07, 2020 Authors M. Jasans‐Barceló P. Curman L. Hagströmer J.D. Wikstrom D. Sairaf Institution Södersjukhuset Hospital, Karolinska Institute Disease Hailey-Hailey
Hailey-Hailey disease (HHD), or familial benign pemphigus, is a rare autosomal dominant acantholytic dermatosis characterized by blistering, and erythematous, erosive and macerated plaques located primarily in intertriginous areas. Secondary bacterial and viral infections are common. There is no "gold standard" treatment, although many therapeutic modalities have been proposed....
Low-Dose Naltrexone reduces symptoms in Stiff-Person Syndrome
Research Type Human Reported as Case Report/Series/Restrospective Study Date January 07, 2020 Authors Mauro Zappaterra, Elizabeth Shouse, Reed Loring Levine Institution Synovation Medical Group, VA Greater Los Angeles Healthcare System, Harmonae Psychological Services, Inc. Disease SPS (Stiff Person Syndrome)
Stiff-Person Syndrome (SPS) is a rare neurologic disorder characterized by severe and progressively worsening muscle stiffness and rigidity. SPS can be very painful due to unpredictable muscle spasms which can be triggered by various stimuli, such as noise, touch, or emotional experiences. There is thought to be an autoimmune component to the disorder. We present the case of a 59-year-old woman diagnosed with SPS who appears to have experienced a dramatic reduction in her symptoms after being tr...
Low-dose naltrexone as a treatment for chronic fatigue syndrome
Research Type Human Reported as Case Report/Series/Restrospective Study Date January 06, 2020 Authors MJ Bolton, BP Chapman, H van Marwijk Institution Brighton and Sussex Medical School Disease CFS
Naltrexone is used as an off-label treatment in low doses for several chronic immune-modulated disorders in many countries. Although only small-scale clinical trials have been performed, these suggest efficacy in several diseases including Crohn's disease, fibromyalgia and Gulf War Illness. Despite numerous internet reports of response to low-dose naltrexone (LDN), no clinical trials exist in people with chronic fatigue syndrome. This condition is characterised by chronic profound fatigue, poste...
The effect of low-dose naltrexone on solid Ehrlich carcinoma in mice: The role of OGFr, BCL2, and immune response
Research Type Animal Reported as Clinical Trial Date December 14, 2019 Authors Alshimaa Aboalsoud, Sabah H. El-Ghaiesh, Fleur F. Abd Elmonem, Mohammed L.Salem, Mohamed N. Abdel Rahmana Institution Tanta University, University of Tabuk, Bisha University Disease Cancer (general)
AIMS: Cancer is a major worldwide health problem. Cancer cells express opioid growth factor (OGF) which controls their growth. Naltrexone in low dose (LDN) blocks opioid receptors intermittently and controls the replication of cancer cells. The aim of this study was to investigate the effect of LDN and its chemotherapeutic additive effect on the growth of solid Ehrlich carcinoma in mice with focus on the OGFr and immune responses. MAIN METHODS: Sixty female Swiss albino mice were assigned into ...
Low-dose naltrexone in the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)
Research Type Human Reported as Case Report/Series/Restrospective Study Date November 19, 2019 Authors Olli Polo, Pia Pesonen, Essi Tuominen Institution University of Tampere, Unesta Clinic and Research Center Disease CFS
BACKGROUND: Myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS) is a common medical condition that limits physical and cognitive functions, with no known effective medical treatment. METHODS: We report on the safety and effectiveness data accumulated in clinical practice when treating ME/CFS with low-dose naltrexone (LDN, 3.0 – 4.5 mg/day). The medical records from 218 patients who received ar diagnosis of ME/CFS and LDN treatment during 2010–2014 were retrospectively analyzed. ...
Low-dose naltrexone safe, effective for neuropathic corneal pain
Research Type Human Reported as Case Report/Series/Restrospective Study Date October 25, 2019 Authors Gabriella Dieckmann, M. Cuneyt Ozmen, Ryan Engert, Melina Morkin, Pedram Hamrah Institution Tufts University Disease Neuropathic Corneal Pain
"Treatment with low-dose naltrexone resulted in improvements in pain and quality of life scores without serious side effects among patients with neuropathic corneal pain," according to a presenter at the American Academy of Ophthalmology annual meeting (Oct 11-15, 2019; San Francisco). “Neuropathic corneal pain is a disease that causes nerve damage and results in pain or discomfort,” Gabriela Dieckmann, MD, from the department of ophthalmology at Tufts Medical Center, said. “Low-dose nalt...
Changes in the consumption of antiepileptics and psychotropic medicines after starting low dose naltrexone: A nation-wide register-based controlled before-after study
Research Type Human Reported as Case Report/Series/Restrospective Study Date October 21, 2019 Authors Guttorm Raknes, Lars Småbrekke Institution University Hospital of North Norway, Raknes Research, UiT - The Arctic University of Norway Disease Psychiatric Conditions
In this controlled before-after study based on data from the Norwegian Prescription Database, we examine whether starting off-label use of Low Dose Naltrexone (LDN) is followed by changes in the consumption of psychotropic medicines including antiepileptics. Patients that collected LDN for the first time in 2013 (N = 11247) were included and stratified into three groups based on LDN exposure. We compared differences in means of cumulative number of defined daily doses (DDD) as well as change...
Low-dose naltrexone-induced remission in Hailey–Hailey disease maintained in remission with topical combination of ketamine and diphenhydramine
Research Type Human Reported as Case Report/Series/Restrospective Study Date September 24, 2019 Authors Sidharth Sonthalia, Mahima Agrawal, Ankur Talwar, Mohamad Goldust Institution Mazandaran University of Medical Sciences; HIMS Institute, LHMC and Associated Hospitals, Skinnocence Skin Clinic and Research Centre Disease Hailey-Hailey
Recent anecdotal evidence suggests that oral low-dose naltrexone (LDN) is effective for Hailey–Hailey disease (HHD) but suffers the limitation of immediate relapse following cessation of the medication. With lack of safety data on long-term administration of LDN, we explored the utility of a topical diphenhydramine/ketamine (DK) cream in maintaining the remission achieved with LDN. A 42-year-old male with treatment-refractory HHD remitted with 5 mg naltrexone/day but relapsed on stopping the d...
A Retrospective Review of Patients Prescribed Low Dose Naltrexone for Chronic Pain at a Single Institution
Research Type Human Reported as Case Report/Series/Restrospective Study Date September 20, 2019 Authors Anne McKenzie-Brown, Ezihe Agwu, Vinita Singh Institution Emory University School of Medicine Disease Chronic Pain
INTRODUCTION: Safe and effective alternatives are needed to long-term opioids for the treatment of chronic pain.(1) Low dose naltrexone (LDN) has unique analgesic properties with few side effects. LDN temporarily blocks intrinsic opioid receptors with rebound increase in beta endorphin and methionine enkephalin (Met-Enkephalin) receptors. LDN is also an immune modulator, working at the level of the glial cell as a toll like receptor 4 (TLR4) antagonist.(2) The most commonly reported dose related...